Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. - Wikidata - wikimedia - TriplyDB

Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.

Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.

http://www.wikidata.org/entity/Q42645982

about

Indacaterol, a once-daily beta2-agonist, versus twice-daily beta2-agonists or placebo for chronic obstructive pulmonary disease Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline.Maximum type 1 error rate inflation in multiarmed clinical trials with adaptive interim sample size modifications Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study.Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials.Safety of indacaterol in the treatment of patients with COPD.Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.Indacaterol (arcapta neohaler) for chronic obstructive pulmonary disease Indacaterol in chronic obstructive pulmonary disease: an update for clinicians.Indacaterol: a comprehensive review.Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine New developments in the management of COPD: clinical utility of indacaterol 75 μg.Role of indacaterol, a once-daily bronchodilator, in chronic obstructive pulmonary disease.Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.An update on the use of indacaterol in patients with COPD.Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD.Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease.Indacaterol: a new long-acting β2-agonist in the management of chronic obstructive pulmonary disease.Indacaterol: a novel long-acting β(2) -agonist.Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation.Turning a molecule into a medicine: the development of indacaterol as a novel once-daily bronchodilator treatment for patients with COPD.Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis-driven selection rules.Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials.Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches.A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpoints.Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.A varying-stage adaptive phase II/III clinical trial design.A model-based longitudinal meta-analysis of FEV1 in randomized COPD trials.Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.Adaptive designs: The Swiss Army knife among clinical trial designs?

P2860

Q24186652-BDCFF0E7-12BB-416F-AC8D-63344EDBC76A Q24197853-E83AF946-0E7D-4AF6-92D8-011C62673E8D Q24200476-F6DB9EB7-073A-429C-9262-FBCD25C4AF46 Q27348844-D1C0A601-F642-4263-9A07-DAADF101C268 Q28652785-3A4638DF-D997-43D0-83DB-B584CE816ACC Q33912856-9CE45EDB-B4CF-4D5B-B2C5-29F6DFB4305D Q34049219-AD76BCB7-40B1-4768-B93D-8395A0870DC7 Q34544020-8FE911B3-F060-4F5B-AAF7-CBF6680ED246 Q34686851-30CB1DFE-32C8-4A15-882D-DF5F69A684AE Q35268351-FD1D436A-8C45-4352-8C81-BD7EA468333D Q35822146-080C1A0D-D3A3-4A27-A215-88F28D76F6D8 Q35958673-2EC6DBAA-C3EA-4C07-B9A4-6C3F695BED92 Q36443777-712F452C-EA05-4464-AF81-6DCC52B14686 Q37057061-70A9B774-9733-4243-BBFD-2BDD2BB660C9 Q37199477-A50655AC-E587-42AE-9987-7654B51D8CDF Q37390883-2EEF7E36-5C54-4367-A98F-7260420E02B7 Q37457359-53D74B5E-5E5B-43A3-ACE4-E988C25AF7F5 Q37773997-E365C34D-4460-48A7-8912-769B5DC08157 Q37804908-41674E3B-31A9-42C7-B3AE-5A69BF18E633 Q37808058-F3CE7C8F-2218-4826-82B8-A5BA666068D3 Q37846698-C17AD1D5-AB32-4D3B-BC5A-FE295B5B13D6 Q37896372-1EE8F87B-B93A-4DAE-9EE7-DD35F3865CCB Q37987211-49075CC2-3F8E-4750-B7FF-540FA34412D7 Q37999465-DC140E05-C303-4317-9786-4CCA8DEA21B8 Q38002357-A42E131B-5BF2-4161-B038-E9CBEA20B4CF Q38072277-9B809BD3-A004-4559-A2D9-4CD88922373F Q38148145-1F1A5056-232C-4459-8B1F-B53166CC25B9 Q38167828-E47A5E71-C51B-4CE8-AFAF-AF323BE12A53 Q38248438-839BFA21-A5F9-46BC-A214-1DBA9A1C9CF2 Q38380750-BD1ECE55-1976-472A-B0BD-3933EE1B344A Q38528288-EB3467F3-A4F2-4BD0-84B3-8CD45ED093F8 Q39831868-84DC9AEB-9130-43EB-AC8E-45BB1B7D69E9 Q39961475-B24E2965-AE29-459C-A654-AA3144F0DCC9 Q41815663-967ACF05-3189-4151-B525-E2476E68358C Q42130183-C773F754-95D3-45EE-90A7-11310A497123 Q42170464-F303311A-F2DE-450A-A6F6-06A8C111335D Q44494327-38D8A9F5-A0F3-4B89-A21E-0ABD70BED309 Q44494841-237718C8-D02A-49CC-ADB6-6D8C831CBDAA Q46942791-D7D3ADD1-2C81-4192-B4DA-69A39BBDE266 Q47856748-CD78D9ED-6A17-4579-9577-AEFA8DED5660

P2860

Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.

http://www.wikidata.org/entity/Q42645982

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Integrating indacaterol dose s ...... g an adaptive seamless design.

@en

Integrating indacaterol dose s ...... g an adaptive seamless design.

@nl

type

label

Integrating indacaterol dose s ...... g an adaptive seamless design.

@en

Integrating indacaterol dose s ...... g an adaptive seamless design.

@nl

prefLabel

Integrating indacaterol dose s ...... g an adaptive seamless design.

@en

Integrating indacaterol dose s ...... g an adaptive seamless design.

@nl

P1433

Q42645982-5F7CE1CB-1888-4E5E-9FBE-0B04DDC5D74F

P1476

Q42645982-659E7D14-1069-47AB-BDF2-E06F92ED9B71

P2093

Q42645982-6B419349-79F2-4C34-B27D-4A4A011C3696

Q42645982-AF7A8D28-E35E-456D-BBCC-2414A9E86DAE

Q42645982-B39CE749-0608-4AAC-9B6F-09EB70949641

Q42645982-D9637172-3A77-49A8-A196-20CF4B1B075C

Q42645982-E2830D20-7DAF-4848-9639-CB7F16051B26

Q42645982-E55B8E13-915F-4894-AFFB-6CB7AB0868E2

Q42645982-FEB2982D-7FF2-44A0-9790-E5550558C253

P304

Q42645982-08533B11-164E-49E8-997D-A558C2732B56

P31

Q42645982-AD20F744-E0CF-4820-8282-2DF50CE37E5B

P356

Q42645982-DF8CEB49-1B65-4203-88B5-D5BAC124D2A2

P433

Q42645982-FCB892D2-C4C0-4118-8B72-843FC3256103

P478

Q42645982-D94CCF0A-22B1-4D6F-9C7B-34E7DF12DA1D

P577

Q42645982-1C4B876C-A498-4676-8A03-8A9C8388FF64

P5875

Q42645982-C8298EC2-4D1D-41D3-9718-A0A370562AD4

P698

Q42645982-63429576-6FC4-4D77-A221-61B4A65B95B2

P356

J.PUPT.2010.01.003

P1433

Pulmonary Pharmacology & Therapeutics

P1476

Integrating indacaterol dose s ...... g an adaptive seamless design.

@en

P2093

Amir Iqbal

http://www.w3.org/2001/XMLSchema#string

Benjamin Kramer

http://www.w3.org/2001/XMLSchema#string

David Lawrence

http://www.w3.org/2001/XMLSchema#string

Helgo Magnussen

http://www.w3.org/2001/XMLSchema#string

Mark Higgins

http://www.w3.org/2001/XMLSchema#string

Peter J Barnes

http://www.w3.org/2001/XMLSchema#string

Stuart J Pocock

http://www.w3.org/2001/XMLSchema#string

P304

165-171

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PUPT.2010.01.003

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41039868

http://www.w3.org/2001/XMLSchema#string

P698

20080201

http://www.w3.org/2001/XMLSchema#string